sevenspikes.themes.common.filters
sevenspikes.themes.common.closemenu

AZD5363,≥99% (HPLC)

Capivasertib;(S)-4-氨基-N-(1-(4-氯苯基)-3-羟丙基)-1-(7H-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-甲酰胺;(S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

CAS:1143532-39-1;MDL:MFCD22628785;分子式:C21H25ClN6O2;分子量:428.9500
制造商品牌: BSZH 科学公司
货号(SKU): A06206
CAS号: 1143532-39-1
MDL号: MFCD22628785
增值税发票 √ 免费送货 √ 订货电话:010-68689484
¥1,416.00

产品描述

本品可溶于DMSO(86mg/mL)

General description

一种有效的pan-AKT激酶抑制剂,抑制Akt1、Akt2和Akt3,IC50分另为3nM、8nM和8nM。

AZD5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components。

AZD5363是一种可口服的丝氨酸/苏氨酸蛋白激酶AKT(蛋白激酶B)抑制剂,具有潜在的抗肿瘤活性。 AKT抑制剂AZD5363结合并抑制所有AKT亚型。 抑制AKT可阻止介导细胞过程(例如细胞分裂,细胞凋亡以及葡萄糖和脂肪酸代谢)的AKT底物的磷酸化。 由于多种信号成分的突变,多种实体和血液系统恶性肿瘤显示PI3K / AKT / mTOR信号失调。

Properties

Iupac Name(S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Inchi Code1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
Inchi KeyJDUBGYFRJFOXQC-KRWDZBQOSA-N


安全信息

风险声明 (欧洲) 23/24/25
安全声明 (欧洲) 26-36
WGK德国 WGK 3
商品规格
属性名称属性值
储存温度 Storage temp.-20°C低温冷冻
全球实时库存 Availability √美国St. Louis ≥ 33 | 欧洲Eur. ≥ 27 | 東京Tokyo ≥ 9 | 香港与北京 ≥ 16